ArticleJournal of family medicine and primary care2025
To study the role of triglyceride glucose index (TyG Index) as a novel biomarker in patients of type 2 diabetes mellitus (T2DM) developing acute coronary syndrome (ACS).
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To study the role of the triglyceride glucose (TyG) index as a novel biomarker in patients with type 2 diabetes mellitus (T2DM) developing acute coronary syndrome (ACS). Methods: This was a cross-sectional, case-control study conducted over 1 year with a sample size of 175 T2DM subjects divided into cases and controls at a ratio of 2:5 (50 cases: T2DM with ACS, 125 controls: T2DM without ACS). The TyG index was calculated using the formula Ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg (dL)/2]. Result: In this study, nearly half of the patients had ST-elevation myocardial infarction with a male preponderance. The TyG index was significantly higher in the ACS group. Body mass index, fasting blood sugar, serum cholesterol, and serum urea levels were significantly higher in the cases. The TyG index showed a strong correlation with ACS, and linear regression analysis identified it as the strongest risk factor for ACS in these patients, with a cutoff value of 8.9, providing 99% sensitivity and specificity. Interestingly, high-sensitivity CRP levels were not significantly different between the two groups. Conclusion: The TyG index, derived from fasting triglycerides and blood glucose, is a simple and cost-effective marker for insulin resistance (IR) and cardiovascular risks. It is comparable to other markers in predicting conditions such as coronary artery disease (CAD) and atherosclerosis and can be incorporated into the routine clinical evaluation of T2DM patients to predict the risk of ACS, which remains a leading cause of cardiovascular morbidity and mortality in T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.